Page 375 - Special Topic Session (STS) - Volume 4

STS1080 Mahmoud Rafea et al.
22. Naylor, S., 2003. Biomarkers: current perspectives and future prospects.
525–529. doi: 10.1586/14737159.3.5.525
23. http://www.biomarkersconsortium.org.
24. World Health Organization, 2001. Biomarkers in risk assessment: Validity
and validation.
25. Aebersold, R., Anderson, L., Caprioli, R., Druker, B., Hartwell, L. and Smith,
R., 2005. Perspective: a program to improve protein biomarker discovery
for cancer. Journal of proteome research, 4(4), pp.1104-1109.
26. Polanski, M. & Anderson, N. L. A list of candidate cancer biomarkers for
targeted proteomics. Biomark. Insights 2007; 2, 1–48.
27. Füzey, A. K., Levin, J., Chan, M. M., Chan, D. W. Translation of proteomic
biomarkers into FDA approved cancer diagnostics: issues and challenges.
Clin. Proteomics 2013; 10, 13–27.
28. Menon, U. et al. Risk algorithm using serial biomarker measurements
doubles the number of screen-detected cancers compared with a single-
threshold rule in the United Kingdom Collaborative Trial of Ovarian
cancer screening. J. Clin. Oncol. 2015; 33, 2062–2075.
29. Pavlou, M. P., Diamandis, E. P., Blasutig, I. M. The long journey of cancer
biomarkers from the bench to the clinic. Clin. Chem. 2013; 59, 147–157.
30. Kamel, H.F.M. and Al-Amodi, H.S.B., 2016. Cancer Biomarkers. In Role of
Biomarkers in Medicine. IntechOpen.
31. Schiffman, J.D., Fisher, P.G. and Gibbs, P., 2015. Early detection of cancer:
past, present, and future. Am Soc Clin Oncol Educ Book, 35(1), pp.57-65.
32. World Health Organization, 2008. Cancer Control: Knowledge Into Action:
WHO Guide for Effective Programmes. Policy and Advocacy. Module 6
(Vol. 6). World Health Organization.
33. Brennan, D.J., O'connor, D.P., Rexhepaj, E., Ponten, F. and Gallagher, W.M.,
2010. Antibody-based proteomics: fast-tracking molecular diagnostics in
oncology. Nature Reviews Cancer, 10(9), p.605.
34. Neagu, M., Constantin, C., Tanase, C. and Boda, D., 2011. Patented
biomarker panels in early detection of cancer. Recent patents on
biomarkers, 1(1), pp.10-24.
35. Vlahou, A., 2013. Network views for personalized medicine.
PROTEOMICS–Clinical Applications, 7(5-6), pp.384-387.
36. Frantzi, M., Bhat, A. and Latosinska, A., 2014. Clinical proteomic
biomarkers: relevant issues on study design & technical considerations in
biomarker development. Clinical and translational medicine, 3(1), p.7.
37. Rafea, M. and Souchelnytskyi, S., 2012. Rediscovering Red Blood Cells:
Revealing Their Dynamic Antigens Store and Its Role in Health and
Disease. In Blood Cell-An Overview of Studies in Hematology.
IntechOpen.
38. Rafea, M., Zaki, H. and Sultan, T., 2010, November. Bioinformatics data
mining tool using data collected from red blood cells hemolysate. In

364 | I S I W S C 2 0 1 9